Imidazoquinolines with improved pharmacokinetic properties induce a high IFNα to TNFα ratio in vitro and in vivo

TLR Agonists have promising activity in preclinical models of viral infection and cancer. However, clinical use is only in topical application. Systemic uses of TLR-ligands such as Resiquimod, have failed due to adverse effects that limited dose and thus, efficacy. This issue could be related to pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Keppler, Manuel, Straß, Simon, Geiger, Sophia, Fischer, Tina, Späth, Nadja, Weinstein, Thilo, Schwamborn, Anna, Guezguez, Jamil, Guse, Jan-Hinrich, Laufer, Stefan, Burnet, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319141/
https://www.ncbi.nlm.nih.gov/pubmed/37409123
http://dx.doi.org/10.3389/fimmu.2023.1168252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319141/
https://www.ncbi.nlm.nih.gov/pubmed/37409123
http://dx.doi.org/10.3389/fimmu.2023.1168252

Ejemplares similares